Kodiak Sciences (KOD, Financial) remains committed to its strategic goals as it enters the first quarter of 2025. The company is preparing to discuss its advancements during an Investor R&D Update on July 16, 2025, at 1:00 PM Eastern Time. The focus will be on the execution of Kodiak 2.0, a visionary step for the pre-commercial stage biotech firm targeting retinal diseases. Kodiak is advancing with three Phase 3 assets that are expected to generate key topline data in 2026.
The company concluded the first quarter with cash reserves amounting to $138.9 million. Management is optimistic that these funds will sufficiently cover the company’s ongoing and projected activities through 2026.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Kodiak Sciences Inc (KOD, Financial) is $7.25 with a high estimate of $20.00 and a low estimate of $2.00. The average target implies an upside of 84.01% from the current price of $3.94. More detailed estimate data can be found on the Kodiak Sciences Inc (KOD) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, Kodiak Sciences Inc's (KOD, Financial) average brokerage recommendation is currently 3.2, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
